Endometrial Adenocarcinoma
Oncology
2
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Monoclonal Antibody
1100%
+ 1 programs with unclassified modality
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
Acrivon TherapeuticsACR-368
Bristol Myers SquibbNivolumab
Clinical Trials (2)
Total enrollment: 24 patients across 2 trials
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
Start: Aug 2022Est. completion: Apr 2027
Phase 2Recruiting
Study of BMS-986205 and Nivolumab in Endometrial Cancer or Endometrial Carcinosarcoma That Has Not Responded to Treatment
Start: Sep 2019Est. completion: Sep 202624 patients
Phase 2Active Not Recruiting
Related Jobs in Oncology
Senior Research Associate, Immuno-Oncology
SystImmune
1h ago
$60K - $85K/yr
Research Associate I/II, Immuno-Oncology
SystImmune
1h ago
Office Administrator
SystImmune
1h ago
$60K - $80K/yr
Scientist/Sr Scientist
TwoStep Therapeutics
San Carlos
1h ago
Senior Medical Project Manager (m/f/d)
Mindpeak
Hamburg
1h ago
Working Student Active Sourcing Support (m/f/d)
Mindpeak
Hamburg
1h ago
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 24 patients
2 companies competing in this space